Suppr超能文献

在CHO糖基化突变细胞系中合成的重组HIV包膜的生物学特性。

Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines.

作者信息

Fenouillet E, Miquelis R, Drillien R

机构信息

CNRS URA 1455, Faculté de Médecine Nord, Marseille, 13015, France.

出版信息

Virology. 1996 Apr 1;218(1):224-31. doi: 10.1006/viro.1996.0182.

Abstract

N-glycosylation of the human immunodeficiency virus type-1 envelope (Env) glycoprotein precursor (gp160) occurs by transfer of Glc3Man9GlcNAc2 onto the nascent protein. Maturation then occurs via cleavage of the three Glc residues, which starts during translation. These events are considered necessary to create Env functional conformation: treatment with "alpha"-glucosidase inhibitors, but not alpha-mannosidase inhibitors (i) impairs gp160 cleavage into gp120 and gp41, (ii) diminishes the accessibility of gp120 V3 region, (iii) prevents gp120 binding to its CD4 receptor, and (iv) prevents gp41-mediated membrane fusion. These inhibitors are of therapeutic interest. Here, using a collection of parent and mutant CHO cells that possess mutations in different steps of glycosylation, we reassessed the role of glycans in both the processing and the properties of recombinant gp160 expressed from a vaccinia virus vector. Mutant cells were as follows: Lec23 (which lacks alpha-glucosidase I activity) produces a collection of triglucosylated structures (Glc3Man7-9GlcNAc2); LEC10 (which has increased GlcNAc transferase III activity) produces complex glycans with a bisected GlcNAc residue; Lec1 (which lacks GlcNAc transferase I) and Lec3.2.8.1 (which lacks GlcNAc transferase I and has decreased activity of CMP-NeuNAc and UDP-Gal translocases) produce Man5GlcNAc2 glycans at complex or hybrid sites. As expected, glycosylation of Env produced from mutants was affected but, irrespective of the glycosylation phenotype, (i) similar quantities of Env were synthesized, (ii) the immunoreactivity of V3 was similar, (iii) gp160 was efficiently cleaved into gp120 and gp41, (vi) Env was exposed at the cell membrane, (v) secreted gp120 bound CD4, and (vi) membrane gp41 was able to induce membrane fusion with CD4+ cells. Thus, the glycosylation alterations examined are dispensable for Env processing and biological activity in CHO cells. In particular, removal of the three outer Glc residues was not required per se for Env folding in this system because functional Env is obtained from Lec23 cells: it appears therefore that lack of modification is not equivalent to drug inhibition of modification. These data are discussed in the light of previous reports describing the use of glycosidase inhibitors to alter glycosylation.

摘要

人类免疫缺陷病毒1型包膜(Env)糖蛋白前体(gp160)的N-糖基化是通过将Glc3Man9GlcNAc2转移到新生蛋白上实现的。随后,通过切割三个葡萄糖残基发生成熟过程,该过程在翻译期间开始。这些事件被认为是形成Env功能构象所必需的:用“α”-葡萄糖苷酶抑制剂而非α-甘露糖苷酶抑制剂处理(i)会损害gp160切割成gp120和gp41,(ii)降低gp120 V3区域的可及性,(iii)阻止gp120与其CD4受体结合,以及(iv)阻止gp41介导的膜融合。这些抑制剂具有治疗意义。在这里,我们使用了一系列在糖基化不同步骤具有突变的亲本和突变CHO细胞,重新评估了聚糖在痘苗病毒载体表达的重组gp160的加工和特性中的作用。突变细胞如下:Lec23(缺乏α-葡萄糖苷酶I活性)产生一系列三葡萄糖基化结构(Glc3Man7-9GlcNAc2);LEC10(GlcNAc转移酶III活性增加)产生带有平分GlcNAc残基的复杂聚糖;Lec1(缺乏GlcNAc转移酶I)和Lec3.2.8.1(缺乏GlcNAc转移酶I且CMP-NeuNAc和UDP-Gal转运酶活性降低)在复杂或杂合位点产生Man5GlcNAc2聚糖。正如预期的那样,突变体产生的Env糖基化受到影响,但无论糖基化表型如何,(i)合成的Env量相似,(ii)V3的免疫反应性相似,(iii)gp160有效地切割成gp120和gp41,(iv)Env暴露于细胞膜,(v)分泌的gp120结合CD4,以及(vi)膜gp41能够诱导与CD4 +细胞的膜融合。因此,所检测的糖基化改变对于CHO细胞中Env的加工和生物学活性是可有可无的。特别是,在该系统中,Env折叠本身并不需要去除三个外层葡萄糖残基,因为从Lec23细胞可获得功能性Env:因此似乎缺乏修饰并不等同于药物抑制修饰。根据先前描述使用糖苷酶抑制剂改变糖基化的报告对这些数据进行了讨论。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验